Search Within

Sergio Andres Giralt

  1. "Andriy Derkach"
Formats
  1. Meeting Abstract (51)
  2. Journal Article (12)
  3. Research Letter (4)
  4. Correspondence (2)
Groups
  1. Biostatistics Service (69)
  2. Bone Marrow Transplant (69)
  3. Center for Hematologic Malignancies (69)
  4. Department of Medicine (69)
  5. Epidemiology and Biostatistics (69)
  6. Hematologic Malignancies, Division of (69)

More Groups

People
  1. Andriy Derkach (69)
  2. Alexander Lesokhin (65)
  3. Carlyn Rose Tan (65)
  4. Malin Hultcrantz (65)
  5. Sham Mailankody (65)
  6. Urvi Shah (65)

More People

Years
  1. 2025 (5)
  2. 2024 (16)
  3. 2023 (17)
  4. 2022 (16)
  5. 2021 (9)
  6. 2020 (6)
Publications
  1. Blood (28)
  2. Clinical Lymphoma, Myeloma and Leukemia (17)
  3. Journal of Clinical Oncology (6)
  4. Blood Cancer Journal (5)
  5. American Journal of Hematology (3)
  6. Blood Advances (2)

More Publications

Publishers
  1. American Society of Hematology (30)
  2. Elsevier Inc. (19)
  3. American Society of Clinical Oncology (6)
  4. Nature Publishing Group (5)
  5. John Wiley & Sons, Inc. (3)
  6. Taylor & Francis Group (2)

More Publishers

Results (69)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes in frail patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma
    Journal Article

    Adegbite, B.; Tan, C. R.; Shekarkhand, T.; Firestone, R. S.; Jurgens, E. M.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; Rajeeve, S.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Belantamab mafodotin in patients with relapsed/refractory multiple myeloma: A real-world experience
    Journal Article

    Hultcrantz, M.; Derkach, A.; Hassoun, H.; Korde, N.; MacLachlan, K.; Mailankody, S.; Patel, D.; Shah, U. A.; Tan, C. R.; Chung, D. J.; more...
    Blood Neoplasia (2025)

    Fulltext@MSK | Save
  • Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma
    Correspondence

    Sebastian, T.; Rajeeve, S.; Farzana, T.; Firestone, R.; Jurgens, E.; Miller, K.; Costa, B.; Lesokhin, A.; Tan, C.; Shah, G.; more...
    Blood Cancer Journal (2025)

    Fulltext@MSK | Save
  • Restarting teclistamab and talquetamab after prolonged dose delay may not require re–step-up dosing
    Research Letter

    Tan, C. R.; Wang, A.; Nemirovsky, D.; Derkach, A.; Shekarkhand, T.; Hamadeh, I.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Evaluating serum free light chain ratio as a biomarker in multiple myeloma
    Journal Article

    Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A. M.; Hassoun, H.; Lu, S. X.; Patel, D.; Shah, U. A.; Tan, C. R.; more...
    Haematologica (2025)

    Fulltext@MSK | Save
  • Belantamab mafodotin, nirogacestat and pomalidomide for patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Hultcrantz, M.; Hassoun, H.; Tan, C. R.; Korde, N.; Lesokhin, A. M.; Hashmi, H.; Maclachlan, K. H.; Rajeeve, S.; Shah, U. A.; Patel, D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Daratumumab versus lenalidomide as maintenance therapy in newly diagnosed multiple myeloma- Interim efficacy results of a randomized clinical trial
    Meeting Abstract

    Rajeeve, S.; Derkach, A.; Devlin, S. M.; Santos, J.; Przemielewska, A.; Sood, T.; Maclachlan, K. H.; Hashmi, H.; Tan, C. R.; Korde, N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Immune-MRD status informs tumor-MRD outcome prognostication in multiple myeloma patients on lenalidomide maintenance
    Meeting Abstract

    Firestone, R. S.; Simhal, A. K.; McAvoy, D.; Jurgens, E. M.; Garcés, J. J.; Nemirovsky, D.; Derkach, A.; Maclachlan, K. H.; Hultcrantz, M.; Mailankody, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A high-fiber dietary intervention (NUTRIVENTION) in precursor plasma cell disorders improves biomarkers of disease and may delay progression to myeloma
    Meeting Abstract

    Shah, U. A.; Cogrossi, L. L.; Derkach, A.; Castro, F.; Fei, T.; DeWolf, S.; Garces, J. J.; Policastro, A.; Grioni, M.; Sisti, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Comparison of acute kidney injury in patients with relapsed or refractory multiple myeloma following CAR T-cell and bispecific antibody therapies
    Meeting Abstract

    Nishimura, N.; Mailankody, S.; Nemirovsky, D.; Derkach, A.; Costa, B. A.; Farzana, T.; Shaikh, A.; Latcha, S.; Gutgarts, V.; Jurgens, E. M.; more...
    Blood (2024)

    Fulltext@MSK | Save